Aussie/Kiwi M&A/Events

Aussie/Kiwi M&A/Events

Mayne Pharma (MYX AU): Gedeon Richter (0QFP LN)'s Full Offer

Quiddity Research's avatar
Quiddity Research
Nov 17, 2026
∙ Paid
  • On the 21st Feb 2025, Mayne Pharma (MYX AU) entered into a Scheme with US-based pharmaceutical outfit, Cosette Pharmaceuticals, at A$7.40/share. Then the wheels fell off.

  • As discussed in Mayne Pharma (MYX AU): This One’s On You Jim As Court Dismisses Cosette’s Appeal, if not for the Treasurer dinging the deal, Cosette had no legal out.

  • Mayne has now entered into a SID with Gedeon Richter (0QFP LN) at A$6.40/share, a punchy 99.4% premium to undisturbed. Looks clean. Expected implementation late March 2027.

Mayne Pharma (MYX AU) is not super illiquid - look away now if this is not your thing.


The Trade:

  • At A$5.92/share, I see the current/gross spread of 8.1%/23.7%, assuming late March completion.

  • That’s attractive.

  • Risk to the deal is one of timing, as it relates to various reg approvals.

Keep reading with a 7-day free trial

Subscribe to Aussie/Kiwi M&A/Events to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2026 Quiddity Investment Advisors · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for writing, podcasting, and media founders.